Leiutis Pharmaceuticals announces CDSCO approval for Global-First Synthetic CBD Therapy for Mild to Moderate Anxiety Disorders

▴ Dr. Jagadeesh Babu Rangisetty, Chief Executive Officer, Biophore India Pharmaceuticals & K. Chandrasekhar, CEO & Managing Partner, Leiutis Pharmaceuticals LLP.
The first globally approved synthetic cannabidiol oral solution 150mg/ml prescription by psychiatrists only for the management of mild to moderate anxiety disorders, used in conjunction with cognitive behavioural therapy.
National | July 14th, 2026: Leiutis Pharmaceuticals LLP, a speciality therapeutics company, has announced that the Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to collaboration partner Zenara Pharma to manufacture its proprietary Synthetic Cannabidiol Oral Solution 150 mg/mL for the management of mild to moderate anxiety disorders when used in conjunction with cognitive behavioural therapy (CBT). The product is to be prescribed only by psychiatrists.
The approval is based on a successful Phase III clinical trial conducted in India in accordance with CDSCO requirements and will be followed by a Phase IV study. Leiutis said it marks the world's first regulatory approval of a fully synthetic cannabidiol oral solution for the management of mild to moderate anxiety disorders. The product was researched, developed, patented and clinically validated entirely in India.
The product combines a synthetic cannabidiol active pharmaceutical ingredient (API), developed by Biophore India Pharmaceuticals, with Leiutis' proprietary nanodispersible drug delivery platform, manufactured at Zenara's CDSCO-, FDA-, and EU-compliant facilities. The company said the product represents end-to-end pharmaceutical innovation achieved in India, spanning API development, drug delivery, clinical development, and regulatory approval.
“This approval reflects nearly a decade of dedicated cannabinoid research, encompassing the development of a proprietary synthetic cannabinoid API manufacturing process, innovative drug-delivery technology, and a robust body of preclinical and clinical evidence. Developed entirely in India and protected by patents in key markets, this approval is a significant milestone for our innovation pipeline, paving the way for next-generation cannabinoids. We thank the Government of India, clinical investigators, researchers and study participants who made it possible,” said K. Chandrasekhar, CEO & Managing Partner, Leiutis Pharmaceuticals LLP.
Biophore India Pharmaceuticals developed the synthetic cannabidiol API manufacturing process and has filed a United States Drug Master File (US DMF), reflecting internationally recognised quality standards.
Commenting on the development, Dr. Jagadeesh Babu Rangisetty, Chief Executive Officer, Biophore India Pharmaceuticals, said, "We are proud that this global first was developed in India. The journey from concept to approval demanded scientific perseverance, continuous learning and close collaboration at every stage. This approval reinforces India's capability to deliver globally relevant pharmaceutical innovation from discovery through commercialisation."
The approved product contains a fully synthetic cannabidiol (CBD) API, with no cannabis plant material used. Leiutis noted that cannabidiol is recognised as non-psychoactive and has no abuse or dependence potential, distinguishing it from other psychoactive products.
The approval comes at a time when anxiety disorders remain a significant public-health challenge in India. The National Mental Health Survey 2015–16, conducted by NIMHANS across 12 states and various publications, reported a current prevalence of 2.57% and a lifetime prevalence of 3.5% for anxiety disorders among adults. These reports and surveys also identified treatment gaps across mental disorders ranging from 28% to 83%, underscoring the need for timely diagnosis, effective treatment and continuity of mental healthcare.
Commenting on the approval, Dr. Sanjay Sharma, President - Corporate Strategy & Growth, Leiutis Pharmaceuticals, said: “We are delighted with CDSCO approval and look forward to making this therapy available to patients across India through psychiatrists and our collaborative ecosystem. We remain committed to expanding access to novel treatments and advancing mental healthcare across the country.”
The approval further strengthens Leiutis' proprietary innovation pipeline in neuropsychiatry, pain management and oncology.
Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026